Dataset Information

Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID).

ABSTRACT:

Introduction

The COVID-19 pandemic has led to over 100 million cases worldwide. The UK has had over 4 million cases, 400 000 hospital admissions and 100 000 deaths. Many patients with COVID-19 suffer long-term symptoms, predominantly breathlessness and fatigue whether hospitalised or not. Early data suggest potentially severe long-term consequence of COVID-19 is development of long COVID-19-related interstitial lung disease (LC-ILD).

Methods and analysis

The UK Interstitial Lung Disease Consortium (UKILD) will undertake longitudinal observational studies of patients with suspected ILD following COVID-19. The primary objective is to determine ILD prevalence at 12 months following infection and whether clinically severe infection correlates with severity of ILD. Secondary objectives will determine the clinical, genetic, epigenetic and biochemical factors that determine the trajectory of recovery or progression of ILD. Data will be obtained through linkage to the Post-Hospitalisation COVID platform study and community studies. Additional substudies will conduct deep phenotyping. The Xenon MRI investigation of Alveolar dysfunction Substudy will conduct longitudinal xenon alveolar gas transfer and proton perfusion MRI. The POST COVID-19 interstitial lung DiseasE substudy will conduct clinically indicated bronchoalveolar lavage with matched whole blood sampling. Assessments include exploratory single cell RNA and lung microbiomics analysis, gene expression and epigenetic assessment.

Ethics and dissemination

All contributing studies have been granted appropriate ethical approvals. Results from this study will be disseminated through peer-reviewed journals.

Conclusion

This study will ensure the extent and consequences of LC-ILD are established and enable strategies to mitigate progression of LC-ILD.

SUBMITTER: Wild JM

PROVIDER: S-EPMC8461362 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID).

Wild Jim M JM Porter Joanna C JC Molyneaux Philip L PL George Peter M PM Stewart Iain I Allen Richard James RJ Aul Raminder R Baillie John Kenneth JK Barratt Shaney L SL Beirne Paul P Bianchi Stephen M SM Blaikley John F JF Brooke Jonathan J Chaudhuri Nazia N Collier Guilhem G Denneny Emma K EK Docherty Annemarie A Fabbri Laura L Gibbons Michael A MA Gleeson Fergus V FV Gooptu Bibek B Hall Ian P IP Hanley Neil A NA Heightman Melissa M Hillman Toby E TE Johnson Simon R SR Jones Mark G MG Khan Fasihul F Lawson Rod R Mehta Puja P Mitchell Jane A JA Platé Manuela M Poinasamy Krisnah K Quint Jennifer K JK Rivera-Ortega Pilar P Semple Malcolm M Simpson A John AJ Smith Djf D Spears Mark M Spencer LIsa G LG Stanel Stefan C SC Thickett David R DR Thompson A A Roger AAR Walsh Simon Lf SL Weatherley Nicholas D ND Weeks Mark Everard ME Wootton Dan G DG Brightling Chris E CE Chambers Rachel C RC Ho Ling-Pei LP Jacob Joseph J Piper Hanley Karen K Wain Louise V LV Jenkins R Gisli RG

BMJ open respiratory research 20210901 1

<h4>Introduction</h4>The COVID-19 pandemic has led to over 100 million cases worldwide. The UK has had over 4 million cases, 400 000 hospital admissions and 100 000 deaths. Many patients with COVID-19 suffer long-term symptoms, predominantly breathlessness and fatigue whether hospitalised or not. Early data suggest potentially severe long-term consequence of COVID-19 is development of long COVID-19-related interstitial lung disease (LC-ILD).<h4>Methods and analysis</h4>The UK Interstitial Lung D ...[more]

PMID: 34556492

Similar Datasets

Project description:Rationale: The natural history of recovery from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains unknown. Because fibrosis with persistent physiological deficit is a previously described feature of patients recovering from similar coronaviruses, treatment represents an early opportunity to modify the disease course, potentially preventing irreversible impairment.Objectives: Determine the incidence of and describe the progression of persistent inflammatory interstitial lung disease (ILD) following SARS-CoV-2 when treated with prednisolone.Methods: A structured assessment protocol screened for sequelae of SARS-CoV-2 pneumonitis. Eight hundred thirty-seven patients were assessed by telephone 4 weeks after discharge. Those with ongoing symptoms had outpatient assessment at 6 weeks. Thirty patients diagnosed with persistent interstitial lung changes at a multidisciplinary team meeting were reviewed in the interstitial lung disease service and offered treatment. These patients had persistent, nonimproving symptoms.Results: At 4 weeks after discharge, 39% of patients reported ongoing symptoms (325/837) and were assessed. Interstitial lung disease, predominantly organizing pneumonia, with significant functional deficit was observed in 35/837 survivors (4.8%). Thirty of these patients received steroid treatment, resulting in a mean relative increase in transfer factor following treatment of 31.6% (standard deviation [SD] ± 27.6, P < 0.001), and forced vital capacity of 9.6% (SD ± 13.0, P = 0.014), with significant symptomatic and radiological improvement.Conclusions: Following SARS-CoV-2 pneumonitis, a cohort of patients are left with both radiological inflammatory lung disease and persistent physiological and functional deficit. Early treatment with corticosteroids was well tolerated and associated with rapid and significant improvement. These preliminary data should inform further study into the natural history and potential treatment for patients with persistent inflammatory ILD following SARS-CoV-2 infection.

Dataset Information

Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID).

Introduction

Methods and analysis

Ethics and dissemination

Conclusion

Publications

Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID).

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets